Axogen Announces Proposed Public Offering of Common Stock

Core Viewpoint - Axogen, Inc. plans to offer and sell $85.0 million of its common stock in a proposed underwritten public offering, with an additional option for underwriters to purchase up to $12.75 million more [1][2] Group 1: Offering Details - The proposed offering is subject to market conditions and other factors, with no assurance on the completion or terms of the offering [1] - Wells Fargo Securities and Mizuho are the lead book-running managers, while Canaccord Genuity and Raymond James are co-managers for the offering [2] - The offering is made under an automatic shelf registration statement that became effective upon filing with the SEC on January 21, 2026 [3] Group 2: Use of Proceeds - Axogen intends to use the net proceeds from the offering for early payoff and termination of its term loan facility with Oberland Capital, working capital, capital expenditures, and other general corporate purposes [2] Group 3: Company Overview - Axogen focuses on the science, development, and commercialization of technologies for peripheral nerve repair, aiming to make nerve repair the expected standard of care [5] - The company's product portfolio includes various nerve repair solutions such as Avance® nerve grafts and Axoguard® products [6]